$CPB

Dorrance Bennett JR purchased $6K of CPB (indirect holdings)

Dorrance Bennett JR purchased 300 indirectly-held shares of CAMPBELL'S Co (CPB) at $21.45 across 3 trades on 2026-06-09.

Original reporting
SEC EDGAR · Dorrance Bennett JR
Published Jun 10, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CPB
Bullish
high confidence
Mentioned
$CPB
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CPBBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase (300 shares total) at a stated price; it may slightly influence sentiment but does not change fundamentals by itself.

02

Market read

A director open-market buy is a modest bullish datapoint, but the transaction size is small and provides no new guidance or event risk.

03

What to watch

Because the transaction is modest and lacks new operational/financial information, traders may over-weight it versus earnings, margins, or macro demand signals.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-10; purchase dated 2026-06-09.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Campbell’s (CPB).

Company-level read

Ticker impact

$CPBBullishHigh confidence
Context

SEC Form 4 shows director Dorrance Bennett JR bought 300 shares of Campbell’s (CPB) on 2026-06-09 at $21.45/share.

Expected impact

Low likelihood of a near-term price catalyst; any impact would be sentiment-driven and limited.

Evidence & confidence

The disclosure is a routine insider purchase with modest dollar value ($6.4k) and no accompanying guidance, deal, or regulatory event.

Market effects

No sector-level read-across; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned behavior; this one is small and not under a 10b5-1 plan.

Key entities

  • Campbell’s Co

    CPB, the company whose shares were purchased by a director.

  • Dorrance Bennett JR

    Director who executed the open-market purchase disclosed on Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CPBMedAI 8/10

Campbell's Q4 Earnings Call Highlights

Campbell Soup Company (CPB) reported Q4 results, highlighting 5% growth in semi-scratch cooking, led by Swanson, Pacific, and Rao's. U.S. soup consumption rose 0.9%, with premium brands Pacific and Rao's growing 14% and 25.3%, respectively. Snacks division faced pressure, with organic net sales declining 6%. The company plans cost savings, a dividend reset, and expects fiscal 2027 net sales to decline 2-4%.

$CPBHighAI 8/10

Campbell's forecasts weak year ahead on pressured consumer spending

Campbell Soup Company (CPB) forecasted weaker-than-expected annual profit and sales, citing soft demand for pricier snacks. The company cut its quarterly dividend by over a third and announced cost-saving measures, including plant closures and workforce reductions. CEO Mick Beekhuizen acknowledged unsatisfactory results and plans to adjust prices to reflect commodity cost changes. Analysts noted the company's aggressive self-help stance. Lower-income consumers are shifting to cheaper alternative

$SNOWMed

Stocks making the biggest moves premarket: Snowflake, Moderna, Broadcom & more

Snowflake shares surged 24% after Q2 results beat estimates, with revenue of $1.55B and EPS of $0.62. Broadcom fell 2.5% on lower Q4 revenue forecasts. Campbell's dropped 7% on weak fiscal 2027 guidance. Ultragenyx plunged 46% after a failed drug trial. Petco rose 9% on strong Q2 margins. Moderna declined 2% after a downgrade. Argan gained 7.5% on better-than-expected earnings. Five Below rose 4.5% on strong Q2 results. Victoria's Secret fell 18% on missed revenue estimates. Netskope rose 12% on

$CPBMedAI 8/10

Campbell’s forecasts annual sales below estimates on weak consumer spending

Campbell Soup Company (CPB) issued annual forecasts below estimates, citing weak demand for higher-priced products. The company expects fiscal 2027 net sales to fall 2-4%, below analysts' estimate of a 0.8% drop. Q4 net sales declined 8% to $2.1B. CPB cut its quarterly dividend by over a third to 25 cents and aims for $500M in cost savings by 2030. Adjusted profit per share is forecast at $2.17, above analysts' estimate of $1.86.